Skip to main content

Hematopoietic Stem Cell Transplantation

5
Pipeline Programs
7
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
1
ATGPhase 41 trial
BusulfanN/A1 trial
Active Trials
NCT04786002Unknown500Est. Jun 2023
NCT01883180Completed412Est. Jan 2018
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
caspofunginPhase 2
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
caspofunginPhase 21 trial
Active Trials
NCT00148148Completed75Est. Dec 2007
MSD
MSDIreland - Ballydine
1 program
1
caspofunginPhase 2
TME Pharma
TME PharmaGermany - Berlin
1 program
1
NOX-A12Phase 11 trial
Active Trials
NCT01194934Completed12Est. Jan 2011
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Continuous Glucose MonitorN/A1 trial
Active Trials
NCT03037671Completed29Est. Apr 2024
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
caspofunginPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNION therapeuticsATG
Sharp Therapeuticscaspofungin
TME PharmaNOX-A12
UNION therapeuticsBusulfan
Colorado TherapeuticsContinuous Glucose Monitor

Clinical Trials (5)

Total enrollment: 1,028 patients across 5 trials

NCT01883180UNION therapeuticsATG

ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

Start: Jun 2013Est. completion: Jan 2018412 patients
Phase 4Completed
NCT00148148Sharp Therapeuticscaspofungin

A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation

Start: May 2004Est. completion: Dec 200775 patients
Phase 2Completed
NCT01194934TME PharmaNOX-A12

NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers

Start: Aug 2010Est. completion: Jan 201112 patients
Phase 1Completed
NCT04786002UNION therapeuticsBusulfan

Target Busulfan Exposure in Children With HSCT in China

Start: Nov 2020Est. completion: Jun 2023500 patients
N/AUnknown
NCT03037671Colorado TherapeuticsContinuous Glucose Monitor

Evaluation of Malglycemia Via Continuous Glucose Monitoring in the Pediatric HSCT Population

Start: Feb 2017Est. completion: Apr 202429 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.